285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

詳細情報 詳細情報について

• CRID

  1870865117674042880

• DOI

  10.1093/annonc/mdw583.011

• ISSN

  15698041

  09237534

• データソース種別

  • OpenAIRE